Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

SYNergic multimodal platform for high-throughput anti-cancer bOne-metastases theraPy ScreenIngS

Project description

An organ-on-a-chip platform for studying bone metastases

Organs-on-a-chip constitute a significant advancement in biomedical research for studying organ function, disease and therapy response. Their design is aimed at replicating the cellular, mechanical and biochemical properties of a specific organ more accurately than traditional 2D cell cultures. With the support of the Marie Skłodowska-Curie Actions programme, the SYNOPSIS project aims to develop an organ-on-a-chip to model the bone perivascular niche, where breast and prostate cancer cells frequently metastasise. The device will capture the mechanical and electrical properties of cancer cells as well as mimic fluid shear stress. Applications of the SYNOPSIS model include high-throughput screening of therapies and support of personalised anti-metastatic treatments.

Objective

Cancer is currently the second cause of death worldwide; however, the World Health Organization expects it to become the first one by 2060. Breast and Prostate Cancers (BC and PC) are highly aggressive tumours linked to top cancer-related mortality rates in the world, with the skeletal tissue as one of the primary sites of metastasis.

This project, called SYNOPSIS, an acronym for “SYNergic multimodal platform for high-throughput anti-cancer bOne-metastases theraPy ScreenIngS”, aims at studying therapeutic agents against BC and PC in the perivascular niche around the bone-tissue within a lab-on-chip, with a multimodal approach involving time-lapse microscopy (TLM) and impedance optical-deformability cytometry (IODC).

The proposed project is divided into four key phases:
1. Organ-on-chip platform: design, fabrication, and testing of the microphysiological system (MPS), including the culturing of bone and cancer cells under fluid shear stress conditions and the administration of chemotherapeutic agents.
2. IODC: design, fabrication, and testing of the module.
3. Data acquisition: TLM videos of the cells in the MPS and IODC measurements.
4. Data Analysis: optimise processing strategies for TLM and IODC data to leverage the various signals available for evaluating therapy efficacy.

The action will bring: (1) a new MPS, mimicking cancer in the bone perivascular niche, overcoming literature’s limitations; (2) a novel IODC platform probing cell’s electro-mechanical features; (3) a first-time combination of TLM and IODC measurements in MPS. The principal objective of this action will be the realization of a multimodal platform for anti-cancer bone-metastases drug-efficacy evaluation (4), combining TLM video, IODC with a minimum of 10^3 cells/s, and data analysis reaching 95% accuracy on test data coming from independent experiments, providing the user with the rationale of the decision process, finally decreasing cancer-related mortality.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-GF - HORIZON TMA MSCA Postdoctoral Fellowships - Global Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2024-PF-01

See all projects funded under this call

Coordinator

UNIVERSITA DEGLI STUDI DI ROMA TOR VERGATA
Net EU contribution
€ 412 700,52
Address
VIA CRACOVIA 50
00133 Roma
Italy
Region
Centro (IT) Lazio Roma
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Partners (1)